Lysosomes are membrane-bound degradative compartments that break down macromolecules from endocytic,
phagocytic and autophagic pathways, and serve the role of key metabolic and signaling hubs. Accumulating
evidence suggests that in Alzheimer's disease and other neurodegenerative disorders lysosomes fail to
correctly perform their functions. However, due to the paucity of tools to study organelles in vivo, so far
there has been no systematic assessment of lysosomal alterations during progression of Alzheimer's
disease, and the exact molecular nature of the proposed impairments is not known. Our understanding of the
involvement of the lysosome in the disease is further limited because lysosomes are rare, constituting <3% of the
cell.
Here, we seek to combine powerful, state-of-the-art approaches including recently developed rapid lysosomal
isolations (LysoIPs) and unbiased proteomic and metabolomic analyses to determine if and how lysosomes
change in vivo in murine models of Alzheimer's disease. We propose to focus on lysosomes isolated from
neurons and microglia which we expect to be critical to the pathology of the disease. Complex reciprocal
interactions between neurons and microglia are essential for regulation of the most important aspects of brain
function, and we hypothesize that alterations of the endolysosomal systems in these two cell types
compromise the integrity of the central nervous system. Here, in Aim I we propose to define lysosomal
alterations in neurons and microglia over a time course of Alzheimer's disease progression generating a dynamic
atlas of lysosomal proteins and metabolites in these cells. This aim will generate novel mouse models and robust
protocols enabling rapid lysosomal isolations from neurons and microglia. In Aim 2 we will validate
bioinformatically filtered candidates from Aim 1, paving the way for future mechanistic dissections.
The proposed research utilizes innovative technologies and concepts to address fundamental molecular
aspects of pathobiology of Alzheimer's disease, building a comprehensive atlas of in vivo lysosomal changes
in neurons and microglia. We believe that this work will shed light on novel aspects of lysosomal biology in the
brain and has the potential to transform our understanding of the mechanistic basis of Alzheimer's disease,
informing future developments in the treatment of this devastating disorder.